The unifying objective of this project is to determine whether peanut oral immunotherapy (PN
OIT) induced clinical tolerance in the context of food allergy is significantly associated
with the expansion of a specific regulatory T cell subset (CD45RA- CD25++ FoxP3++) that is
thought to be inducible in the gut-associated lymphoid compartment and associated with
immunological tolerance.
The hypothesis of the study is that the induction of Treg cells will be associated with
clinical tolerance.
The investigators will measure the change from baseline of induced Treg cells as a frequency
of total CD4 T cells during active treatment and compare that between participants who
achieve significant clinical tolerance (Tolerance and Partial Tolerance Groups as defined
below) and those who do not (Treatment Failure Group).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)